Biotech Execs Speak Out Against Trump’s Immigration Ban; Big Pharma Remains Mostly Silent
Executive Summary
Letter initiated by six CEOs drew 'absolutely overwhelming' response as 163 leaders of primarily small biotech and venture capital firms signed on; tech firms join court fight.
You may also be interested in...
Anatomy Of A Biotech Company: Acorda Gets Dressed For A Second Act
Acorda's rise, fall, and attempt to rise again is a snapshot of the life of a biotech. The company reached the commercial-stage pinnacle with Ampyra, only to eventually see it fall away to patent challenges. Now, after big staff cuts, the company is hoping to prevail in the commercial market again, this time with Inbrija.
Anatomy Of A Biotech Company: Acorda Gets Dressed For A Second Act
Acorda's rise, fall, and attempt to rise again is a snapshot of the life of a biotech. The company reached the commercial-stage pinnacle with Ampyra, only to eventually see it fall away to patent challenges. Now, after big staff cuts, the company is hoping to prevail in the commercial market again, this time with Inbrija.
Carrots and Stick: Biopharma At The White House
Drug industry executives discuss drug pricing and tax and regulatory reform in a high-profile meeting with President Trump at the White House.